—
SummaryVentilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia (VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing amounts of oxygen in the blood).
GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1613806-ventilator-associated-pneumonia-vap-pipeline-review-h2-2017
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ventilator Associated Pneumonia (VAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 9, 5, 11, 1 and 1 respectively.
Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (VAP) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Ventilator Associated Pneumonia (VAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ventilator Associated Pneumonia (VAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ventilator Associated Pneumonia (VAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ventilator Associated Pneumonia (VAP) (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ventilator Associated Pneumonia (VAP) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Content: Key Points
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Ventilator Associated Pneumonia (VAP) - Overview 6
Ventilator Associated Pneumonia (VAP) - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Products under Development by Companies 11
Ventilator Associated Pneumonia (VAP) - Therapeutics Assessment 13
Assessment by Target 13
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Ventilator Associated Pneumonia (VAP) - Companies Involved in Therapeutics Development 21
Achaogen Inc 21
Adenium Biotech ApS 21
Aridis Pharmaceuticals LLC 22
AstraZeneca Plc 22
Bayer AG 23
Cardeas Pharma Corp 23
Destiny Pharma Ltd 24
…Continued
ACCESS REPORT @ https://www.wiseguyreports.com/reports/1613806-ventilator-associated-pneumonia-vap-pipeline-review-h2-2017
For accessing accurate and deep understanding and to gain latest insights and key developments in the area of your interest, we also have a list of conferences in which you will be interested in, for more information, cordially check:
https://www.wiseguyreports.com/conferences
For updating knowledge or for thoroughly understanding various terminologies, we also have vast list of seminars for your reference, for more information cordially check:
https://www.wiseguyreports.com/seminars
Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WISEGUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers Pune - 411028 Maharashtra, India
Phone: +44 208 133 9349
Website: http://www.wiseguyreports.com
Release ID: 220929
Google
RSS